MBIO

Mustang Bio Inc. (MBIO) | Rumor.io

Mustang Bio

MBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#4,892

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.63

Market capitalization3.8M

Earnings per share-0.42

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-1.9M

Social

What share of all stock conversation is about MBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Feb 5

The company's stock may experience a significant increase due to potential news, possibly announced on Friday or Monday.
The company has a substantial amount of cash, with an estimated net cash per share of $2.37, which may contribute to its low stock price.
The stock has seen unusually high trading volume, with some speculating that this may be a sign of insider knowledge or a major announcement.

Generated by AI

Sentiment

Of the messages about MBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.55% -1.69
Bearish	—	—	—	20.45% +1.69

Bullish· Jul 9

$MBIO has a strong chart with a potential breakout at $3.73.
A potential partnership with a leading pharmaceutical company could cause the stock to explode.
The stock is setting up for another move up, possibly reaching $5.5 or $6.60.

Bearish· Jul 9

The asset has experienced a significant 20% drop in a short period, raising concerns about market integrity.
The company's news and announcements have been met with skepticism, with some traders perceiving them as a means to manipulate the market.
The asset's price has been subject to volatile fluctuations, with some traders expressing frustration at the rapid decline and difficulty in making gains.

Generated by AI

Topics

Of the messages about MBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	73.2%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	26.8%

Announcements· Jul 7

Mustang Bio, Inc. (MBIO) received Orphan Drug Designation from the FDA for its IL13Ra2-targeted CAR T-cells, MB-101, to treat astrocytomas and glioblastoma.
The ongoing Phase 1 trial of MB-101 showed promising results, with 50% of patients achieving stable disease or better, including two partial responses and two complete responses lasting 7.5 and 66+ months.
The company plans to further develop its MB-109 program for recurrent GBM and high-grade astrocytomas, contingent upon raising additional funding or consummating a strategic partnership.

Technical Analysis· Jul 7

The author believes $MBIO has a high chance of breaking $4 and testing its high of the day in after-hours trading.
The stock has a strong momentum, with a price increase of 107.63% and high volume, making it a potential candidate for a breakout.
The author is waiting for $MBIO to close above $3.40-$3.50, which would be a green flag technically, and is watching for signs such as Bollinger Bands squeezing, RSI climbing, and MACD curling.

Generated by AI

Community

Of the messages about MBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	25.51%
Newcomers	—	—	100%	74.49%

Regulars· Jan 2

The stock ran from 15c to $1.30 on a previous instance of high volume, with 150M+ shares traded.
Regulars have been achieving 70% gains on quick moves, noting nice returns on both $LGHL and $MBIO.
The stock saw a net inflow of $1.69M "smart money" on 01/01/2025, resulting in an 18.02% price change.

Newcomers· Nov 13

New investors are focusing on the strong volume supporting the upward price trend in MBIO, indicating a potential continuation of the current momentum.
Some newcomers are analyzing the stock's chart pattern, suggesting a possible ascending triangle formation, which could lead to a breakout and increased price movement.
Others are observing the recent 2.46% gain in MBIO and considering the potential for an RSI rally, which could be triggered by continued buying pressure.

Generated by AI

Also Discussed

Investors talking about MBIO also mention

#	Name	Attention
1	Fortress Biotech, Inc.FBIO	0%0
2	Journey Medical Corp. Common StockDERM	0%0
3	Akoustis Technologies Inc.AKTS	0%new
4	CKPT - Checkpoint Therapeutics, Inc.	——
5	ENDRA Life Sciences Inc.NDRA	0%0
6	Crown Electrokinetics Corp.CRKN	0%0
7	ZCAR - Zoomcar Holdings, Inc.	——
8	PRST - Presto Automation, Inc.	——
9	Avenue Therapeutics Inc.ATXI	0%new
10	BRSH - Bruush Oral Care Inc.	——

Mustang Bio Inc.

Healthcare
Biotechnology

Mustang Bio Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for difficult-to-treat cancers and autoimmune diseases. The company’s current programs center on CAR T cell therapies and related oncology platforms designed to target hematologic malignancies, solid tumors, and other serious conditions with high unmet medical need. Mustang Bio works to advance these therapies through research, licensing, and collaboration with medical institutions, positioning itself within the broader precision medicine and immunotherapy markets. Headquartered in Waltham, Massachusetts, Mustang Bio plays a specialized role in the biotechnology sector by translating scientific breakthroughs into potential therapeutic products for patients facing complex and often life-threatening diseases.

Website

Location

95 Sawyer Road

Waltham, MA, 02453

United States

Social

What share of all stock conversation is about MBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Feb 5

The company's stock may experience a significant increase due to potential news, possibly announced on Friday or Monday.
The company has a substantial amount of cash, with an estimated net cash per share of $2.37, which may contribute to its low stock price.
The stock has seen unusually high trading volume, with some speculating that this may be a sign of insider knowledge or a major announcement.

Generated by AI

Sentiment

Of the messages about MBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.55% -1.69
Bearish	—	—	—	20.45% +1.69

Bullish· Jul 9

$MBIO has a strong chart with a potential breakout at $3.73.
A potential partnership with a leading pharmaceutical company could cause the stock to explode.
The stock is setting up for another move up, possibly reaching $5.5 or $6.60.

Bearish· Jul 9

The asset has experienced a significant 20% drop in a short period, raising concerns about market integrity.
The company's news and announcements have been met with skepticism, with some traders perceiving them as a means to manipulate the market.
The asset's price has been subject to volatile fluctuations, with some traders expressing frustration at the rapid decline and difficulty in making gains.

Generated by AI

Topics

Of the messages about MBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	73.2%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	26.8%

Announcements· Jul 7

Mustang Bio, Inc. (MBIO) received Orphan Drug Designation from the FDA for its IL13Ra2-targeted CAR T-cells, MB-101, to treat astrocytomas and glioblastoma.
The ongoing Phase 1 trial of MB-101 showed promising results, with 50% of patients achieving stable disease or better, including two partial responses and two complete responses lasting 7.5 and 66+ months.
The company plans to further develop its MB-109 program for recurrent GBM and high-grade astrocytomas, contingent upon raising additional funding or consummating a strategic partnership.

Technical Analysis· Jul 7

The author believes $MBIO has a high chance of breaking $4 and testing its high of the day in after-hours trading.
The stock has a strong momentum, with a price increase of 107.63% and high volume, making it a potential candidate for a breakout.
The author is waiting for $MBIO to close above $3.40-$3.50, which would be a green flag technically, and is watching for signs such as Bollinger Bands squeezing, RSI climbing, and MACD curling.

Generated by AI

Community

Of the messages about MBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	25.51%
Newcomers	—	—	100%	74.49%

Regulars· Jan 2

The stock ran from 15c to $1.30 on a previous instance of high volume, with 150M+ shares traded.
Regulars have been achieving 70% gains on quick moves, noting nice returns on both $LGHL and $MBIO.
The stock saw a net inflow of $1.69M "smart money" on 01/01/2025, resulting in an 18.02% price change.

Newcomers· Nov 13

New investors are focusing on the strong volume supporting the upward price trend in MBIO, indicating a potential continuation of the current momentum.
Some newcomers are analyzing the stock's chart pattern, suggesting a possible ascending triangle formation, which could lead to a breakout and increased price movement.
Others are observing the recent 2.46% gain in MBIO and considering the potential for an RSI rally, which could be triggered by continued buying pressure.

Generated by AI

Mustang Bio

Social

Feb 5

Sentiment

Bullish· Jul 9

Bearish· Jul 9

Topics

Announcements· Jul 7

Technical Analysis· Jul 7

Community

Regulars· Jan 2

Newcomers· Nov 13

Also Discussed

Mustang Bio Inc.

Company Information

Location

Also Discussed

Social

Feb 5

Sentiment

Bullish· Jul 9

Bearish· Jul 9

Topics

Announcements· Jul 7

Technical Analysis· Jul 7

Community

Regulars· Jan 2

Newcomers· Nov 13